A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms TRIPLE NEGATIVE
- 23 Nov 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 23 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated